CONCLUSIONS: Benefits of sitagliptin treatment in diabetic NOD mice may be mediated through selective effects on subpopulations of T-cells that are related to autoimmunity.doi:10.2337/db09-1618Kim SJNian CMcIntosh CHDiabetes